Patents by Inventor Michael W. Leviten

Michael W. Leviten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HSPC150-like gene disruptions, compositions and methods related thereto
    Patent number: 7164055
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a HSPC150-like gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: January 16, 2007
    Assignee: Deltagen, Inc.
    Inventor: Michael W. Leviten
  • Transgenic mice exhibiting increased susceptibility to seizures
    Patent number: 6653526
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a ubiquitin-specific protease 16 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: November 25, 2003
    Assignee: Deltagen, Inc.
    Inventor: Michael W. Leviten
  • UBE2G2 ubiquitin-conjugating enzyme gene disruptions, compositions and methods related thereto
    Publication number: 20030177514
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a UBE2G gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: June 25, 2002
    Publication date: September 18, 2003
    Inventor: Michael W. Leviten
  • HSPC150-like gene disruptions, compositions and methods related thereto
    Publication number: 20030046721
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a HSPC150-like gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: June 25, 2002
    Publication date: March 6, 2003
    Inventor: Michael W. Leviten
  • USP3-like deubiquitinating enzyme gene disruptions, compositions and methods related thereto
    Publication number: 20030046720
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a USP3-like deubiquitinating enzyme gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: June 25, 2002
    Publication date: March 6, 2003
    Inventor: Michael W. Leviten
  • Transgenic mice containing USP3-like deubiquitinating enzyme gene disruptions
    Publication number: 20030014771
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a USP3-like deubiquitinating enzyme gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: March 28, 2002
    Publication date: January 16, 2003
    Inventor: Michael W. Leviten
  • Transgenic mice containing ubiquitin enzyme gene disruptions
    Publication number: 20030009779
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a ubiquitin enzyme gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: March 28, 2002
    Publication date: January 9, 2003
    Inventor: Michael W. Leviten
  • ADAM-like protease disruptions, compositions and methods related thereto
    Publication number: 20030005474
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in an ADAM-like protease gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: March 28, 2002
    Publication date: January 2, 2003
    Inventor: Michael W. Leviten
  • Transgenic mice containing beta3GalT2 gene disruptions
    Publication number: 20030005477
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a &bgr;3GalT2 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: March 29, 2002
    Publication date: January 2, 2003
    Inventor: Michael W. Leviten
  • Transgenic mice containing ubiquitin protein ligase E3 gene disruptions
    Publication number: 20020194627
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in an ubiquitin ligase E3 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: August 3, 2001
    Publication date: December 19, 2002
    Inventor: Michael W. Leviten
  • Transgenic mice containing cash gene disruptions
    Publication number: 20020174450
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in the CASH gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: December 4, 2001
    Publication date: November 21, 2002
    Inventors: Keith D. Allen, Michael W. Leviten
  • Transgenic mice comprising beta-1,3-N-acetyllactosamine disruptions
    Publication number: 20020170075
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a &bgr;3GnT gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: March 28, 2002
    Publication date: November 14, 2002
    Inventors: Michael W. Leviten, Russell Phillips
  • Transgenic mice containing cerberus gene disruptions
    Publication number: 20020162131
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a cerberus gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: June 21, 2001
    Publication date: October 31, 2002
    Inventors: Michael W. Leviten, Thomas J. Brennan
  • Transgenic mice containing huntingtin interacting protein gene disruptions
    Publication number: 20020133841
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a HIP1 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: December 7, 2001
    Publication date: September 19, 2002
    Inventor: Michael W. Leviten
  • Transgenic mice containing deubiquitinated enzyme gene disruptions
    Publication number: 20020133842
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a deubiquitin protease-like gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: December 7, 2001
    Publication date: September 19, 2002
    Inventor: Michael W. Leviten
  • Transgenic mice containing chordin gene disruptions
    Publication number: 20020038468
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a chordin gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: June 29, 2001
    Publication date: March 28, 2002
    Inventor: Michael W. Leviten
  • Transgenic mice containing ubiquitin-specific protease 16 gene disruptions
    Publication number: 20020032914
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a ubiquitin-specific protease 16 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: July 11, 2001
    Publication date: March 14, 2002
    Inventor: Michael W. Leviten
  • Transgenic mice containing serine protease gene disruptions
    Publication number: 20020026653
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a serine protease gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: July 6, 2001
    Publication date: February 28, 2002
    Inventors: Keith D. Allen, Michael W. Leviten
  • Transgenic mice containing tryptase gene disruptions
    Publication number: 20020026654
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a tryptase gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: July 6, 2001
    Publication date: February 28, 2002
    Inventors: Keith D. Allen, Michael W. Leviten
  • Transgenic mice containing ubiquitin-specific protease gene disruptions
    Publication number: 20020022719
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a ubiquitin-specific protease gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Application
    Filed: July 11, 2001
    Publication date: February 21, 2002
    Inventor: Michael W. Leviten